It has now settled into the 0.017-0.020 range as I predicted.The buying pressure is weakening-should stay in this range for a few months.Should think KSX wouldn't allow the buyside to disappear,so should stay in this range.
Medicine does not taste very nice,but we should take it:a biotech without proven sales revenue will always underwhelm expectations.After all,technically,this baby has been flat-lining for a long time.When our new board can provide some spark we will be away.Until then,we can only dream about universal product uptake!
Good Luck All
It has now settled into the 0.017-0.020 range as I predicted.The...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
